Delivery Order SPE2DB24D2205-SPE2DB25FEEVH
- Not listed
- The Defense Logistics Agency awarded a $7,046.76 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Monovisc 88 mg/4 ml syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by September 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger indefinite delivery...
- The Defense Logistics Agency awarded a $38,034.70 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Monovisc 88 mg/4 ml syringes. The contract, which is not set-aside and was competitively awarded, requires completion by June 18, 2025, with performance to be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $9,521.32 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL units). This firm fixed-price contract, which must be completed by September 10, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively procured without set-aside restrictions, reflecting the contractor's established capability to...
- The Defense Logistics Agency awarded a $1,471.36 delivery order to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 mL syringes on July 25, 2025, with completion scheduled for July 28, 2025. This firm fixed-price contract, which is not set-aside, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $5,761.75 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL quantity). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 24, 2025. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,229.88 on July 29, 2025, for the supply of Monovisc 88 mg/4 ml syringes. This competitive award, with no set-aside designation, represents a firm fixed price contract with an ultimate completion date of July 30, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency awarded a delivery order valued at $2,409.96 to AmerisourceBergen Drug Corp for Monovisc 88 mg/4 ml syringes on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price, non-set-aside contract represents a single delivery order fulfillment under AmerisourceBergen's larger indefinite delivery vehicle with DLA. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a $3,614.94 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Monovisc 88 mg/4 mL syringes (4 mL quantity). This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion by June 2, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This...
- The Defense Logistics Agency awarded a delivery order valued at $3,757.37 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Monovisc 88 mg/4 mL syringes. The order, which represents a child contract under a larger indefinite delivery vehicle, is scheduled for completion by July 30, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This award was made on a firm fixed-price basis with no set-aside designation, indicating it was...
- The Defense Logistics Agency awarded a delivery order valued at $9,019.91 to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Monovisc 88 mg/4 mL syringes. The contract is a firm fixed price delivery order with no set-aside designation, indicating competitive award to a qualified vendor. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 3, 2025. This delivery order...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEEVHDelivery Order
The Defense Logistics Agency awarded a $7,062.93 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Monovisc 88 mg/4 mL syringes. This competitive award, which is non-set-aside, will be performed at the contractor's Conshohocken, Pennsylvania location with an ultimate completion date of July 15, 2025. The contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, holds a comprehensive $999.99 billion IDC with the Defense Logistics Agency valued through December 2026. As a prime contractor for military and veteran healthcare systems, the company supplies a broad portfolio of pharmaceutical products and medical commodities across multiple therapeutic domains. This specific delivery order for Monovisc—a hyaluronic acid-based intra-articular injection used in orthopedic care—reflects the company's ongoing role in supporting Defense Health Agency medical supply requirements through the DLA's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.1k | 7/14/25 |